Release time：Mar 06, 2024
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that it will present the clinical study results on the efficacy and safety of the novel Nectin-4-targeting ADC 9MW2821 for patients with recurrent or metastatic cervical cancer as focused plenary oral presentation at the Society of Gynecologic Oncology (SGO) annual meeting on women's cancer to be held in San Diego, USA, from March 16-18, 2024.
The American Society of Gynecologic Oncology (SGO) is a leading non-profit medical organization in the world dedicated to the study, treatment, and education of gynecologic cancers.
Focused Plenary Oral Presentation
Focused Plenary ll: Encore & More: Cutting Edge Gyn Onc Care in Cervical Cancer
Abstract Title: Efficacy and safety of 9MW2821, an antibody-drug conjugate targeting Nectin-4, monotherapy in patients with recurrent or metastatic cervical cancer: A multicenter, open-label, phase I/II study
Abstract Plenary Presenter: Huijuan Yang (Fudan University Shanghai Cancer Center)
Location: Ballroom 20AB
Date/time:March 16, 2024, 3:00 PM PDT
About 9MW2821
9MW2821 is a site-specific conjugated novel Nectin-4-targeting ADC developed by Mabwell's ADC platform and automated high-throughput hybridoma antibody molecular discovery platform.The drug achieves site-specific modification of antibody through proprietary conjugate technology linkers and optimized ADC conjugation process. After injection, 9MW2821 can specifically bind to Nectin-4 on the cell membrane surface, be internalized and release cytotoxic drug, and induce the apoptosis of tumor cells. Mabwell is conducting multiple clinical studies evaluating the efficacy of 9MW2821 in various indications, including urothelial carcinoma and cervical cancer. Mabwell is the first Chinese enterprise to advance 9MW2821 into Phase 3 clinical trials for the treatment of urothelial carcinoma, making it the second globally in terms of progress. 9MW2821 is also the first therapeutic drug in the world with the same target to disclose clinical efficacy data for indications of cervical cancer and esophageal carcinoma
